CEL-SCI Corporation  

(Public, NYSEAMERICAN:CVM)   Watch this stock  
Find more results for CVM
1.87
+0.08 (4.47%)
Oct 20 - Close
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 1.79 - 1.92
52 week 1.46 - 7.50
Open 1.80
Vol / Avg. 376,011.00/223,174.00
Mkt cap 22.13M
P/E     -
Div/yield     -
EPS -1.30
Shares 11.83M
Beta -1.67
Inst. own 13%
Dec 12, 2017
Q4 2017 CEL-SCI Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 11, 2017
CEL-SCI Corp at Rodman & Renshaw Global Investment Conference
Aug 9, 2017
Q3 2017 CEL-SCI Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -25564.75% -4022.49%
Operating margin -30105.35% -8964.16%
EBITD margin - -8911.45%
Return on average assets -207.79% -84.79%
Return on average equity - -
Employees 43 -
CDP Score - -

Address

8229 Boone Blvd Ste 802
VIENNA, VA 22182-2634
United States - Map
+1-703-5069460 (Phone)
+1-703-5069471 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Officers and directors

Geert R. Kersten Esq. Chief Executive Officer, Treasurer, Director
Age: 56
Bio & Compensation  - Reuters
Patricia B Prichep Senior Vice President - Operations, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
John Cipriano Senior Vice President - Regulatory Affairs
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel H Zimmerman Ph.D. Senior Vice President - Research, Cellular Immunology
Age: 73
Bio & Compensation  - Reuters
Eyal Talor Ph.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Alexander G. Esterhazy Independent Director
Age: 73
Bio & Compensation  - Reuters
Peter R. Young Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters